Beacon Therapeutics Valuation, Funding & Investors

AIRNA is a biotechnology company, based in Cambridge, Massachusetts, and Tübingen, Germany, that develops RNA editing therapeutics through its proprietary RESTORE+ platform. The platform makes precise edits to RNA to introduce beneficial genetic variants or repair disease-causing mutations, producing re-administrable medicines with simplified manufacturing compared to gene therapies. Its lead candidate targets alpha-1 antitrypsin deficiency, a genetic disorder that causes lung and liver disease, with additional programs planned in cardiometabolic conditions.

Convergent Therapeutics is a clinical-stage biotechnology company based in Cambridge, Massachusetts, that develops radiopharmaceuticals for cancer treatment. Its lead program, CONV01-alpha, is a radioantibody that binds to prostate-specific membrane antigen to deliver a radioactive payload selectively to prostate cancer cells while sparing healthy tissue. The company is building a broader pipeline of similar radioantibody therapies targeting prostate cancer and other solid tumors.

Yantai Lannacheng Biotechnology is a Yantai-based biotechnology company that develops class I integrated platforms for diagnosis and therapy using novel nuclear radiopharmaceuticals targeting tumors. The firm advances research in targeted radionuclide therapies and diagnostic agents for oncology applications. Its platform supports development of precision medicines for cancer treatment in China.

TOPI Imaging Technology is a Taiwan-based medical device manufacturer producing optical coherence tomography systems for retinal diagnostics and swept-source optical biometers for intraocular lens calculations. The company's OCT devices image macular degeneration and glaucoma while biometers measure axial length pre-surgery. TOPI supplies systems to ophthalmology clinics in Asia and exports to Europe under ISO 13485 certification.

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. The Group’s product pipeline consisted of three clinical-stage product candidates, including its Core Product, LZ901, and six pre-clinical-stage product candidates.

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Biotheryx is a Boulder-based clinical-stage biopharma developing targeted protein degraders using the PRODEGY platform. The company advances BTX-1188, a first-in-class LFA-1 degrader in phase I for psoriasis and solid tumors, alongside preclinical ITK and IRAKIMID degraders. Biotheryx licenses Cereblon E3 ligase binders for molecular glue and bifunctional PROTACs.